Participated · Series B · Jul 2026

RapidPulse is developing a pulsed (cyclic) aspiration platform and a range of catheter sizes intended to improve clot engagement, removal efficiency and procedural consistency during mechanical thrombectomy for acute ischemic stroke. The company’s system is being evaluated in the TURBO investigational device exemption study, conducted in the United States and Europe to support its U.S. regulatory pathway. RapidPulse plans to expand clinical experience with its system across leading stroke centers as part of that program and may pursue FDA approval if clinical data support a submission. The platform strategy includes continued development of the catheter portfolio and broader clinical use to gather performance data across different patients, clot types and treatment settings. RapidPulse was spun out of medical device incubator Syntheon and is headquartered in Miami. Financially, the company recently raised an oversubscribed $48 million Series B co-led by Medtronic, TechWald Next and S3 Ventures, with additional participation from SBI Investment Company, the Florida Opportunity Fund, and existing investors.

Led · Series A · Apr 2026

Sonire Therapeutics develops a next-generation HIFU therapy system that combines real-time imaging guidance with patented technologies such as a noise-cancellation system, cavitation bubble visualization, a robot-assisted positioning platform and rapid multi-focus scanning. The system is designed to provide precise thermal ablation of tumors in an anesthesia-free, outpatient procedure that can be performed in approximately 20 minutes by a single physician. Sonire positions its therapy as a complement to chemotherapy to potentially prolong overall survival while offering a less invasive alternative to surgery or radiation. Foundational academic work with a prototype (MoonShot-2) demonstrated a 66% disease control rate in advanced or refractory pancreatic and biliary tract cancers and informed the current system. The SUNRISE-I randomized trial (HIFU with chemotherapy vs. chemotherapy alone) is ongoing across seven leading Japanese hospitals. The company holds 25 issued patents and 22 pending, was founded in February 2020 in Tokyo, and is now headquartered in Palo Alto, California; it recently raised $18 million in a Series A to advance clinical, regulatory, and commercialization efforts.

Participated · Series C · Apr 2026

E2 is commercializing the Hēlo® Thrombectomy Platform, designed with a patented dual-action mechanism that integrates aspiration with mechanical clot disruption to deliver large-bore performance through a small-profile catheter. The system is indicated for non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature and supports injection, infusion, and aspiration during procedures. E2 describes the platform as intended to improve procedural efficiency and clinical performance as mechanical thrombectomy adoption grows. With the oversubscribed $80 million Series C, the company plans to scale its commercial organization and continue investments in research and operations. The company is backed by a syndicate including Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments. New board members from the lead investors will join as the company advances commercialization.

Led · Seed · Feb 2026

beHuman is a Miami-based, physician-led platform that combines virtual clinical care, advanced diagnostic testing, and longitudinal health data to identify cancer risk early for patients who are historically under-screened. Its agentic AI automates eligibility checks, scheduling, chart review, and follow-up, reducing clinician workload while maintaining strict clinical oversight and data-privacy safeguards. Covered by most major insurance plans, the service targets insured patients in rural and underserved communities who rarely complete recommended screenings. Early internal results indicate cancer detection rates that exceed national averages, suggesting the model’s clinical effectiveness. The company currently operates across multiple U.S. states, with a footprint in the North and Southeast. Newly secured seed funding will fuel expansion into additional states, deeper partnerships with diagnostic laboratories, further development of the AI workflow engine, and scaling of virtual care teams. The $4 million raise represents its first disclosed institutional round and strengthens its financial position for nationwide growth.

Led · Series A · Feb 2026

Headquartered in Cleveland, Graici builds a comprehensive data network that assembles, secures, and activates individuals’ health, economic, and personal information. Its flagship Adaptive Data Wallet™ leverages agentic AI to automate Medicaid renewals and redeterminations, helping eligible people keep coverage while supplying governments and health plans with verified intelligence to cut waste, fraud, and abuse. The platform emphasizes consent, security, and accountable action, enabling clarity and support "at the speed of need." Graici’s patented resource-matching technology is designed to scale systemic impact from the individual up. The company was founded by Steve McHale, who previously co-founded healthcare big-data pioneer Explorys (acquired by IBM). McHale’s vision is to set a new standard for trust-based data exchange in public benefits administration. No operating metrics such as revenue or user counts were disclosed in the article.